GRI Bio Announces 1-for-28 Reverse Stock Split to Regain Nasdaq Compliance

summarizeSummary

GRI Bio, Inc. will implement a 1-for-28 reverse stock split to increase its share price and meet Nasdaq's minimum bid price requirement, effective January 23, 2026.

check_boxKey Events · Corporate Governance and Compliance · GRI

• Reverse Stock Split Approved

  GRI Bio's board of directors approved a 1-for-28 reverse stock split, previously authorized by stockholders, to consolidate outstanding shares.

• Effective Date

  The reverse stock split will become legally effective at 4:01 p.m. Eastern Time on January 23, 2026, with post-split trading on Nasdaq commencing January 26, 2026.

• Nasdaq Compliance Goal

  The primary purpose of the reverse split is to increase the per share trading price to regain compliance with The Nasdaq Capital Market's minimum bid price requirement for continued listing.

• Share Reduction

  The number of outstanding common shares will be reduced from approximately 15 million to about 536,301, though the total authorized shares will remain unchanged.

auto_awesomeAnalysis · GRI · Life Sciences

GRI Bio's decision to implement a 1-for-28 reverse stock split is a critical action aimed at increasing its share price to meet Nasdaq's minimum bid price requirement and avoid delisting. This aggressive split ratio, coupled with the company trading near its 52-week lows, signals significant financial distress and challenges in maintaining market valuation. While necessary for continued listing, reverse stock splits often carry a negative connotation for investors, potentially leading to further price volatility and reflecting underlying operational or financial difficulties. Investors should monitor the company's ability to sustain its post-split price above the Nasdaq threshold and its broader financial health.